AURKB and melanoma: Moreover, the Western blot results demonstrated that knocking down the expression of AURKB markedly suppressed activation of the BRAF/MEK/ERKs and PI3-K/AKT pathways in both vemurafenib-sensitive (A375 and M249) and vemurafenib-resistant melanoma cell lines (A375R and M249R).